特定气道专用促分解介质与非病毒性慢阻肺急性加重恢复相关
该研究基于伦敦COPD急性加重队列,于2016至2018年纳入患者,在基线、加重时及加重后1、2、6周随访,用液相色谱-串联质谱检测痰中SPMs。68次加重中,病毒性加重症状恢复中位时间21天,长于非病毒性加重的13天(P<0.001);细菌性加重时RvD1显著升高,低RvD1与1周和2周时呼吸道症状迁延相关。
要点
- 病毒性COPD加重症状恢复中位时间21天,长于非病毒性加重的13天。
- 细菌性加重时痰RvD1显著升高,病毒性加重未见此升高。
- 低RvD1水平与加重后1周和2周呼吸道症状迁延相关。
核心结论
- COPD急性加重期间气道SPMs呈动态时间变化。
- RvD1水平降低与呼吸道症状迁延相关。
- SPMs可能是促进加重恢复的潜在治疗途径。
研究设计与样本
- 研究为伦敦COPD急性加重队列研究,招募时间为2016年1月11日至2018年4月30日。
- 参与者在基线、加重起点、1周、2周和6周随访,每次行痰采集、鼻咽拭子、抽血、生活质量问卷和肺功能检查。
- 痰SPMs用液相色谱-串联质谱测定,呼吸道病毒用定量PCR检测,细菌用微生物培养检测。
- 研究期间共纳入68次加重。
主要发现
- 病毒性加重症状恢复中位时间为21天,非病毒性加重为13天(P<0.001)。
- 细菌性加重时加重起点RvD1显著升高,病毒性加重时未见显著升高。
- RvD1水平较低与1周和2周恢复时间点呼吸道症状迁延相关。
- 外源性RvD1显著降低COPD支气管上皮细胞对鼻病毒感染的白细胞介素-6(IL-6)和趋化因子配体8(CXCL8)反应。
临床怎么用
- 监测痰RvD1水平可能有助于识别COPD加重后症状迁延风险较高的患者。
- SPMs尤其是RvD1可能作为促进COPD急性加重恢复的潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process that may be driven by specialized proresolving mediators (SPMs). Objectives: We sought to characterize the temporal change in SPMs in the sputum of patients with COPD during exacerbations, their association with exacerbation triggers, and exacerbation recovery. Methods: Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and April 30, 2018. Participants were reviewed at baseline, exacerbation onset, 1 week, 2 weeks, and 6 weeks during their exacerbation recovery. Sputum collection, nasopharyngeal swabs, phlebotomy, quality-of-life questionnaires, and spirometry were performed at each visit. SPMs were measured in sputum by liquid chromatography-tandem mass spectrometry. Respiratory viruses were measured by quantitative PCR and bacteria by microbiological culture. Measurements and Main Results: There were 68 exacerbations during the study period. Median time to symptomatic recovery was 21 days for viral exacerbations, compared with 13 days in nonviral exacerbations (P < 0.001). There was a significant increase in resolvin D1 (RvD1) at exacerbation onset in bacterial exacerbations but not in viral exacerbations. Lower levels of RvD1 were associated with prolonged respiratory symptoms during the 1-week and 2-week recovery time points. Exogenous RvD1 significantly reduced IL-6 and CXCL8 response to rhinovirus infection in COPD bronchial epithelial cells. Conclusions: There is a dynamic temporal change in airway SPMs during COPD exacerbations. Reduced levels of RvD1 were associated with prolonged respiratory symptoms. SPMs may be a potential therapeutic approach to promote exacerbation recovery.
引用
- Finney, Mah, Duvall, et al. Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations. Am J Respir Crit Care Med. 2025. PMID: 40043205. doi:10.1164/rccm.202407-1325OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。